

Special Issue

Chronic Respiratory Diseases and Lung Cancers: From Pathophysiology to Novel Diagnostic and Therapeutic Approaches

Message from the Guest Editors

Chronic respiratory diseases (CRDs) are complex multifactorial disorders involving the airways and other lung structures. Some of the most common CRDs are chronic obstructive pulmonary disease (COPD), lung fibrosis, asthma, occupational lung diseases, pneumoconiosis, pulmonary hypertension, and lung cancers. The disease can be caused by long-term exposure to tobacco smoke or irritating gases; other risk factors include air pollution, occupational chemicals, dust, and frequent lower respiratory infections during childhood. Investigating pulmonary pathology has been fundamental for understanding clinical disease, remains essential to diagnosing disease, and is required in drug and device development. We invite research papers that will consolidate our understanding of this. The Special Issue will publish full research articles, comprehensive reviews, and shorter perspective articles on all aspects related to the theme of chronic respiratory diseases and lung cancers: from pathophysiology to novel diagnostic and therapeutic approaches.

Guest Editors

Dr. Magdalena Radecka

Institute of Physical Chemistry of the Polish Academy of Sciences, 01-224 Warsaw, Poland

Dr. Karolina H. Czarnecka-Chrebelska

Department of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland

Deadline for manuscript submissions

closed (30 September 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/116027

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).